. . . . . . . "9459"^^ . . . . "10215"^^ . . . . . . . . . . . . . "1"^^ . . . . . . . "Potenciace hypoglykemick\u00E9ho \u00FA\u010Dinku, a tedy v n\u011Bkter\u00FDch p\u0159\u00EDpadech i v\u00FDskyt hypoglyk\u00E9mie, se m\u016F\u017Ee objevit p\u0159i pod\u00E1v\u00E1n\u00ED n\u011Bkter\u00E9ho z n\u00E1sleduj\u00EDc\u00EDch l\u00E9\u010Div\u00FDch p\u0159\u00EDpravk\u016F:\n-\tfenylbutazon, azapropazon a oxyfenbutazon,\n-\tinzul\u00EDn a peror\u00E1ln\u00ED antidiabetika, jako je metformin, \n-\tsalicyl\u00E1ty a p-aminosalicylov\u00E1 kyselina,\n-\tanabolick\u00E9 steroidy a mu\u017Esk\u00E9 pohlavn\u00ED hormony,\n-\tchloramfenikol, ur\u010Dit\u00E9 dlouho p\u016Fsob\u00EDc\u00ED sulfonamidy, tetracykliny, chinolonov\u00E1 antibiotika a klaritromycin,\nkumarinov\u00E1 antikoagulancia,\nfenfluramin,\ndisopyramid,\nfibr\u00E1ty,\nACE inhibitory,\nfluoxetin, inhibitory MAO,\nalopurinol, probenecid, sulfinpyrazon,\nsympatolytika,\ncyklofosfamid, trofosfamid a isofosfamidy,\nmikonazol, flukonazol,\npentoxifylin (vysok\u00E9 d\u00E1vky pod\u00E1van\u00E9 parenter\u00E1ln\u011B),\ntritoqualin."@cs . . .